Program at a Glance
| Time | June 13 (Tue) | June 14 (Wed) | June 15 (Thu) | June 16 (Fri) |
|---|---|---|---|---|
| 08:00-09:00 | Registration (On-site) | - | - | |
| 09:00-09:10 | Welcome Remarks from - ICH President - President of Korea University - President of Korea University Medicine and Executive Vice President for Medical Affairs of Korea University |
|||
| 09:10-09:25 | (current) ICH President Lecture Memorial lecture for Prof. Ho Wang Lee |
(next) ICH President Announcement (09:20 - 09:30) |
||
| 09:25-09:30 | Ho Wang Lee Award Ceremony | J. Dalrymple Award Ceremony | ||
| 09:30-10:05 | Ho Wang Lee Award Lecture Awardee : Dr. Connie Schmaljohn (NIAID, USA) |
Dalrymple Award Lecture Awardee : Dr. Misa Korva (University of Ljubljana, Slovenia) |
Session 5 Diagnosis & emerging hantaviruses (09:30 - 10:00) |
|
| 10:05-10:35 | Session 1 Viral epidemiology, evolution & genetics |
Session 3 Immune responses & pathogenesis |
Oral Presentation 5-1 Diagnosis & emerging hantaviruses (10:00 - 10:35) |
|
| 10:35-11:10 | Coffee Break & Poster Viewing (Removing on Friday) | |||
| 11:10-11:55 | Oral Presentation 1-1 Viral epidemiology, evolution & genetics |
Oral Presentation 3-1 Immune responses & pathogenesis |
Oral Presentation 5-2 Diagnosis & emerging hantaviruses (11:10 - 11:40) |
|
| 11:50-14:30 | Lunch & Poster Viewing International Society for Hantaviruses Meeting (Executive Committee member only) |
Lunch & Poster Viewing (11:50-14:00) |
Closing Remarks (11:40 - 12:00) |
|
| On-site Registration (14:00-18:00) |
Oral Presentation 3-2 Immune responses & pathogenesis (14:00-14:45) |
|||
| 14:30-15:15 | Oral Presentation 1-2 Viral epidemiology, evolution & genetics |
|||
| 15:15-15:45 | Session 2 Replication, transcription, translation & assembly |
Session 4 Vaccines, therapeutics & clinical aspects (14:45-15:15) |
||
| Coffee Break & Poster Viewing (15:15-15:45) |
||||
| 15:45-16:15 | Coffee Break & Poster Viewing | Oral Presentation 4 Vaccines, therapeutics & clinical aspects (15:45-17:15) |
||
| 16:15-17:15 | Oral Presentation 2 Replication, transcription, translation & assembly |
|||
| 17:15~ | Welcome Dinner (17:30 - 19:00) |
Conference Banquet (Sudang samyang faculty house) (17:30 - 20:00) |
||
Program may be subjected to change partially
Viral epidemiology, evolution & genetics
Virus evolution has rapidly expanded, due to the explosive availability of genomic sequencing. Virus evolution is an interdisciplinary field including virology, genomics, evolutionary biology, epidemiology, ecology, and computational biology. Recently, the field of genomic epidemiology is significantly involved in tracking and investigating the emergence of SARS-CoV-2 during the COVID-19 pandemic. In this section, viral epidemiology, evolution, and genetics will provide the broad and deep understanding of hantaviral evolution.
Replication, transcription, translation, & assembly
The life cycle of a virus plays a critical role in understanding the virus-host interaction. The step of the viral life cycle consists of replication, transcription, translation, and assembly. These processes elicit the production of infectious viral particles. In addition, the metabolism of viruses provides strategies for the development of vaccines and therapeutics. This section will discuss the recent advance in hantavirology including replication, transcription, translation, and assembly.
Immune responses & pathogenesis
The defense mechanism of a host bridges innate and acquired immunities against viral infections. A variety of innate immune cells, T cells, and B cells provide antiviral mechanisms to control the hantavirus infection. However, hantaviruses have evolved with strategies at the cellular and molecular aspects to evade the host immune system. The immune evasion of hantaviruses plays a critical role in developing pathological outcomes. This section will discuss the recent advances in the immune responses to hantaviral infection and its pathogenesis.
Vaccines, therapeutics & clinical aspects
Hantavirus infections cause hemorrhagic fever with renal syndrome (HFRS) and hantavirus cardiopulmonary syndrome (HCPS) in humans. There are no effective vaccines and therapeutics against hantaviral diseases although clinical cases occur worldwide. The development of new platform vaccines and therapeutics has been accelerated for prevention and preparedness for the post-COVID-19 pandemic. The clinical aspects of hantavirus-induced diseases contribute to understand the development and strategy of antivirals against hantaviruses. This section will provide a broad and deep knowledge of vaccines, therapeutics, and clinical aspects against hantaviral infections.
Diagnosis & emerging hantaviruses
The establishment of rapid and sensitive diagnostic assays plays a critical role in detecting and characterizing emerging infectious viruses. Recently, advanced technologies, including loop-mediated isothermal amplification and next-generation sequencing, contribute to the development of novel serological and molecular assays for the hantaviral diagnosis. The diagnostics provide rapid responsiveness and preparedness for emerging hantaviral diseases. This section will discuss the recent advance and perspectives of diagnostics and preparedness for hantavirus infections.